Klebsiella pneumoniae (K. pneumoniae) is a typical gram-negative iatrogenic bacterium that often causes bacteremia, pneumonia and urinary tract infection particularly among those with low immunity. Although antibiotics is the cornerstone of anti-infections, the clinical efficacy of β-lactamase and carbapenems drugs has been weakened due to the emergence of drug-resistant K. pneumoniae. Recent studies have demonstrated that host defense plays a critical role in killing K. pneumoniae. Here, we summarize our current understanding of host immunity mechanisms against K. pneumoniae, including mechanical barrier, innate immune cells, cellular immunity and humoral immunity, providing a theoretical basis and the new strategy for the clinical treatment of K. pneumoniae through improving host immunity.
Lysine-specific demethylase 1 (LSD1) is an enzyme that removes lysine methylation marks from nucleosome histone tails and plays an important role in cancer initiation, progression, metastasis, and recurrence. Recent research shows that LSD1 regulates tumor cells and immune cells through multiple upstream and downstream pathways, enabling tumor cells to adapt to the tumor microenvironment (TME). As a potential anti-tumor treatment strategy, immunotherapy has developed rapidly in the past few years. However, most patients have a low response rate to available immune checkpoint inhibitors (ICIs), including anti-PD-(L)1 therapy and CAR-T cell therapy, due to a broad array of immunosuppressive mechanisms. Notably, inhibition of LSD1 turns “cold tumors” into “hot tumors” and subsequently enhances tumor cell sensitivity to ICIs. This review focuses on recent advances in LSD1 and tumor immunity and discusses a potential therapeutic strategy for combining LSD1 inhibition with immunotherapy.
Sepsis is a major cause of mortality in neonates, yet understanding of sepsis-associated immune dysregulation in early life remains limited. Sepsis-induced thymus atrophy results in disruption of T cell development, accompanied by the dysfunction of thymic epithelial cells (TECs). Here, we sought to identify molecular mechanisms underlying TECs dysfunction while induced sepsis in neonatal mice and immortalized TECs cell line (iTECs) via lipopolysaccharide (LPS) treatment. We identified that LPS induced a reduction in thymocytes number starting at the double-negative stage of thymocyte development and significantly reduced numbers of naïve T cells and recent thymic emigrants (RTEs). Further we confirmed the alterations of intrathymic cytokines influencing T cell development and functionality through the FOXN1 signaling pathway upon exposure to LPS ex vivo and in vivo. LPS treatment decreased the number of cortical TECs (cTECs) and medullary TECs (mTECs) by enhancing the apoptosis of cTECs and decreasing the proliferation of mTECs. These findings provide valuable insights for further study on the innate and specific immunity in response to neonatal sepsis.
Listeria monocytogenes (Lm) is a foodborne Gram-positive pathogenic bacterium that primarily causes clinical manifestations such as sepsis, meningitis, and monocytosis. The main susceptible populations include newborns, pregnant women, adults over 40 years old, and immunocompromised individuals. Currently, antibiotic therapy remains the primary clinical treatment, but in recent years the issue of antibiotic resistance has become increasingly prominent. This review summarizes recent advances in host immune mechanisms against Lm infection, focusing on: (1) the defensive roles of host barrier systems (intestinal, blood-brain, and placental barriers); (2) innate immune responses, including pathogen recognition via TLRs/NLRs signaling pathways, macrophage phagocytosis, and NK cell immune surveillance; and (3) adaptive immunity, particularly CD4+/CD8+ T cell-mediated specific immune responses and the long-term protective effects of memory T cells. By systematically elucidating the molecular mechanisms of these immune processes, this review aims to provide novel therapeutic strategies through enhancement of host immune functions for clinical management of Lm infection.
1 June 2026 in Drug Design, Development and Therapy
Hepatocellular carcinoma (HCC) is among the most prevalent malignancies of the digestive system, with a global rising incidence. Hedyotis diffusa Willd and Scutellaria barbata D. Don are classic herb pair in traditional Chinese medicine (TCM) of clearing heat and detoxifying, and is widely applied in the treatment of HCC. Although existing research has confirmed their efficacy against HCC through modulation of apoptosis, proliferation, angiogenesis, and immune responses, it is noteworthy that the combined or newly generated components after the compatibility of the two herbs exhibit even more pronounced therapeutic effects. In order to verify the pharmacological activity of the combination of Hedyotis diffusa Willd and Scutellaria barbata D. Don, it is necessary to try more in vitro and in vivo models. This review synthesizes current evidence on their TCM compatibility principles, pharmacological actions, and related signaling pathways of this herb pair, providing a rigorous theoretical foundation to guide rational clinical application and further translational research on the compatibility mechanism of the Hedyotis diffusa Willd–Scutellaria barbata D. Don herb pair in the treatment of HCC.